Table 3.

Intracerebral hemorrhage among DOAC using patients.

Intracerebral hemorrhage
	Concurrent statin	No. of PQs	No. of events	Crude incidence rate (per 1,000 person-year) (95% CI)	Adjusted incidence rate (per 1,000 person-year) (95% CI)	Adjusted IRR (95% CI)	Adjusted IRD (per 1,000 person-year) (95% CI)
All	No statin	332259	492	5.98 (5.46–6.55)	5.95 (5.26–6.73)	1
	All intensity	238923	275	4.65 (4.12–5.25)	4.65 (4.12–5.25)	0.78 (0.66–0.93)	−1.30 (−2.22 to −0.38)
	High-intensity	79266	78	3.98 (3.17–4.99)	3.98 (3.17–5.00)	0.67 (0.52–0.88)	−1.93 (−3.13 to −0.73)
	Low-to-moderate-intensity	165474	209	5.11 (4.44–5.87)	5.1 (4.44–5.86)	0.86 (0.72–1.03)	−0.84 (−1.84 to 0.17)
Male	No statin	190084	282	5.99 (5.31–6.75)	5.62 (4.84–6.52)	1
	All intensity	135304	164	4.91 (4.20–5.74)	4.9 (4.19–5.73)	0.87 (0.70–1.08)	−0.72 (−1.86 to 0.41)
	High-intensity	45017	45	4.05 (3.01–5.46)	4.04 (3.00–5.45)	0.74 (0.53–1.03)	−1.45 (−2.92 to 0.01)
	Low-to-moderate-intensity	93569	126	5.45 (4.56–6.52)	5.44 (4.55–6.51)	0.96 (0.77–1.22)	−0.2 (−1.48 to 1.08)
Female	No statin	141669	210	5.99 (5.21–6.88)	6.34 (5.22–7.71)	1
	All intensity	103070	109	4.27 (3.52–5.19)	4.27 (3.52–5.18)	0.67 (0.51–0.89)	−2.07 (−3.56 to −0.59)
	High-intensity	34017	33	3.91 (2.76–5.56)	3.92 (2.76–5.57)	0.62 (0.41–0.93)	−2.44 (−4.35 to −0.54)
	Low-to-moderate-intensity	71558	81	4.57 (3.65–5.72)	4.57 (3.65–5.72)	0.73 (0.54–0.97)	−1.73 (−3.30 to −0.16)

DOAC, direct oral anticoagulant; PQ, person-quarter; CI, confident interval; IRR, incidence rate ratio; IRD, incidence rate difference.